PMID- 35663317
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220716
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Estradiol and Hyperhomocysteinemia Are Linked Predominantly Through Part Renal 
      Function Indicators.
PG  - 817579
LID - 10.3389/fendo.2022.817579 [doi]
LID - 817579
AB  - BACKGROUND: Previous studies have shown that estrogen, kidney function, and 
      homocysteine (Hcy) or hyperhomocysteinemia (HHcy) are related to each other. 
      However, the underlying biological mechanisms still remain unclear. We aimed to 
      explore the association between estradiol (E2) and HHcy in the female population, 
      and to further evaluate the mediating role of renal function indicators. METHODS: 
      This unmatched case-control study consisted of 1,044 female participants who were 
      60.60 +/- 12.46 years old. Data on general demographic characteristics, such as 
      age, smoking and drinking status, menopause and so on were collected in a 
      personal interview, and laboratory examinations were performed by well-trained 
      personnel. The mediating effect model was applied to analyze the direct and 
      indirect effects of E2 on Hcy. RESULTS: The average levels of Hcy and E2 of the 
      participants were 12.6 mumol/L and 14.95 pg/ml. There were statistical differences 
      in renal indexes blood urea nitrogen (BUN), serum creatinine (Scr), uric acid 
      (UA), glomerular filtration rate (GFR) and E2 between HHcy group and non-HHcy 
      group. The logistic regression models showed that UA was risk factor for HHcy (P 
      <0.001), GFR and E2 were protective factors for HHcy after adjusting for 
      confounding factors (P <0.001). The indirect effects of E2 on Hcy through UA and 
      GFR accounted for 14.63 and 18.29% of the total impacts of E2 on Hcy. 
      CONCLUSIONS: These data indicated that E2 was a protective factor of HHcy, and 
      the effects of E2 on HHcy may be mediated by renal function indicators UA and 
      GFR.
CI  - Copyright (c) 2022 Niu, Wen, Sun, Yang, Du, Xie, Zhang, Li and Hong.
FAU - Niu, Xiao Na
AU  - Niu XN
AD  - First Affiliated Hospital of Hunan Normal University, Hunan Provincial People's 
      Hospital, Changsha, China.
FAU - Wen, He
AU  - Wen H
AD  - Department of Cardiology, The Second Affiliated Hospital of Air Force Military 
      Medical University, Tangdu Hospital, Xi An, China.
FAU - Sun, Nan
AU  - Sun N
AD  - Department of Cardiology, The Second Affiliated Hospital of Air Force Military 
      Medical University, Tangdu Hospital, Xi An, China.
FAU - Yang, Yi
AU  - Yang Y
AD  - First Affiliated Hospital of Hunan Normal University, Hunan Provincial People's 
      Hospital, Changsha, China.
FAU - Du, Shi Hong
AU  - Du SH
AD  - First Affiliated Hospital of Hunan Normal University, Hunan Provincial People's 
      Hospital, Changsha, China.
FAU - Xie, Rong
AU  - Xie R
AD  - First Affiliated Hospital of Hunan Normal University, Hunan Provincial People's 
      Hospital, Changsha, China.
FAU - Zhang, Yan Nan
AU  - Zhang YN
AD  - First Affiliated Hospital of Hunan Normal University, Hunan Provincial People's 
      Hospital, Changsha, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Cardiology, The Second Affiliated Hospital of Air Force Military 
      Medical University, Tangdu Hospital, Xi An, China.
FAU - Hong, Xiu Qin
AU  - Hong XQ
AD  - First Affiliated Hospital of Hunan Normal University, Hunan Provincial People's 
      Hospital, Changsha, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220518
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 268B43MJ25 (Uric Acid)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Aged
MH  - Case-Control Studies
MH  - Estradiol
MH  - Female
MH  - Humans
MH  - *Hyperhomocysteinemia/complications/epidemiology
MH  - Kidney/physiology
MH  - Middle Aged
MH  - Uric Acid
PMC - PMC9157416
OTO - NOTNLM
OT  - case-control study
OT  - estradiol (E2)
OT  - homocysteine (Hcy)
OT  - hyperhomocysteinemia (HHcy)
OT  - mediation effect
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/07 06:00
MHDA- 2022/06/09 06:00
PMCR- 2022/01/01
CRDT- 2022/06/06 13:57
PHST- 2021/11/18 00:00 [received]
PHST- 2022/01/31 00:00 [accepted]
PHST- 2022/06/06 13:57 [entrez]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.817579 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 May 18;13:817579. doi: 
      10.3389/fendo.2022.817579. eCollection 2022.